Herantis Pharma announces submission of a Clinical Trial Application (CTA) for a Phase 1 study for HER-096
Herantis Pharma Plc, Press release, 19 December 2022 at 2:15 p.m. EET The purpose of the Phase 1 study is to demonstrate safety, tolerability, and blood-brain barrier penetration of HER-096 in human. Herantis Pharma Plc ("Herantis") developing disease-modifying therapies for Parkinson’s disease, announced it submitted a Clinical Trial Application (CTA) today to the Finnish Medicines Agency Fimea, the national competent authority for regulating pharmaceuticals. The Phase 1 study, which includes assessment of safety, tolerability, and blood-brain barrier penetration in healthy